| Primary |
| Product Used For Unknown Indication |
44.3% |
| Hyperlipidaemia |
12.4% |
| Hypercholesterolaemia |
9.3% |
| Type 2 Diabetes Mellitus |
8.2% |
| Blood Cholesterol Increased |
7.2% |
| Pain |
3.1% |
| Carotid Artery Stenosis |
2.1% |
| Generalised Anxiety Disorder |
2.1% |
| Angina Pectoris |
1.0% |
| Blood Cholesterol |
1.0% |
| Coronary Artery Bypass |
1.0% |
| Drug Therapy |
1.0% |
| Erectile Dysfunction |
1.0% |
| Gout |
1.0% |
| Hypertension |
1.0% |
| Nausea |
1.0% |
| Onychomycosis |
1.0% |
| Prophylaxis |
1.0% |
| Urinary Tract Infection |
1.0% |
|
| Rhabdomyolysis |
16.7% |
| Hepatic Enzyme Increased |
8.3% |
| Muscle Spasms |
8.3% |
| Cardiac Failure |
5.6% |
| Drug Interaction |
5.6% |
| Hypokalaemia |
5.6% |
| Joint Swelling |
5.6% |
| Pain In Extremity |
5.6% |
| Parkinsonism |
5.6% |
| Renal Failure Acute |
5.6% |
| Arthralgia |
2.8% |
| Blood Cholesterol Increased |
2.8% |
| Contusion |
2.8% |
| Diabetes Mellitus |
2.8% |
| Fall |
2.8% |
| Gait Disturbance |
2.8% |
| Headache |
2.8% |
| Hypotension |
2.8% |
| Influenza Like Illness |
2.8% |
| Liver Disorder |
2.8% |
|
| Secondary |
| Drug Use For Unknown Indication |
21.7% |
| Product Used For Unknown Indication |
17.0% |
| Hypertension |
12.3% |
| Type 2 Diabetes Mellitus |
10.4% |
| Blood Cholesterol Increased |
7.5% |
| Blood Triglycerides Increased |
6.6% |
| Hypercholesterolaemia |
3.8% |
| Diabetes Mellitus |
2.8% |
| Hyperlipidaemia |
2.8% |
| Anticoagulant Therapy |
1.9% |
| Cardiac Disorder |
1.9% |
| Constipation |
1.9% |
| Prophylaxis |
1.9% |
| Schizophrenia |
1.9% |
| Antiplatelet Therapy |
0.9% |
| Anxiety |
0.9% |
| Asthma |
0.9% |
| Back Pain |
0.9% |
| Blood Cholesterol |
0.9% |
| Depression |
0.9% |
|
| Myalgia |
12.0% |
| Naevus Flammeus |
12.0% |
| Gastrointestinal Neoplasm |
8.0% |
| Arthralgia |
4.0% |
| Bladder Neoplasm |
4.0% |
| Chronic Hepatitis |
4.0% |
| Contusion |
4.0% |
| Dizziness |
4.0% |
| Dysstasia |
4.0% |
| Hepatitis Fulminant |
4.0% |
| Hypotonia |
4.0% |
| Influenza Like Illness |
4.0% |
| Low Density Lipoprotein Increased |
4.0% |
| Muscle Spasms |
4.0% |
| Neutrophil Count Increased |
4.0% |
| Pain In Extremity |
4.0% |
| Pyrexia |
4.0% |
| Respiratory Distress |
4.0% |
| Rhabdomyolysis |
4.0% |
| Self Injurious Behaviour |
4.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.5% |
| Hypertension |
15.2% |
| Drug Use For Unknown Indication |
11.2% |
| Pain |
5.0% |
| Diabetes Mellitus |
4.9% |
| Atrial Fibrillation |
4.6% |
| Blood Cholesterol Increased |
4.2% |
| Rheumatoid Arthritis |
3.6% |
| Type 2 Diabetes Mellitus |
2.7% |
| Coronary Artery Disease |
2.5% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Prophylaxis |
1.9% |
| Blood Cholesterol |
1.8% |
| Arthritis |
1.6% |
| Asthma |
1.6% |
| Multiple Myeloma |
1.6% |
| Osteoporosis |
1.6% |
| Cardiac Failure |
1.5% |
| Depression |
1.5% |
| Gastrooesophageal Reflux Disease |
1.5% |
|
| Vomiting |
9.2% |
| Cardiac Failure |
8.0% |
| Diarrhoea |
6.9% |
| Drug Ineffective |
5.7% |
| Haemoglobin Decreased |
5.7% |
| Myocardial Infarction |
5.7% |
| Renal Failure Acute |
5.7% |
| Weight Decreased |
5.7% |
| Chest Pain |
4.6% |
| Death |
4.6% |
| Ischaemic Stroke |
4.6% |
| Toxicity To Various Agents |
4.6% |
| Visual Impairment |
4.6% |
| Aphasia |
3.4% |
| Asthenia |
3.4% |
| Cerebrovascular Accident |
3.4% |
| Dehydration |
3.4% |
| Fatigue |
3.4% |
| Hypersensitivity |
3.4% |
| Hyponatraemia |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
45.5% |
| Onychomycosis |
27.3% |
| Hypercholesterolaemia |
18.2% |
| Chronic Myeloid Leukaemia |
9.1% |
|
| Atrial Fibrillation |
25.0% |
| Blood Creatine Phosphokinase Increased |
25.0% |
| Drug Interaction |
25.0% |
| Renal Failure Acute |
25.0% |
|
